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Significant advances have lead to a greater understanding of the role of the complement 
system within nephrology. The success of the first clinically approved complement inhib-
itor has created renewed appreciation of complement-targeting therapeutics. Several 
clinical trials are currently underway to evaluate the therapeutic potential of complement 
inhibition in renal diseases and kidney transplantation. Although, complement has 
been known to be activated during dialysis for over four decades, this area of research 
has been neglected in recent years. Despite significant progress in biocompatibility of 
hemodialysis (HD) membranes and peritoneal dialysis (PD) fluids, complement activation 
remains an undesired effect and relevant issue. Short-term effects of complement acti-
vation include promoting inflammation and coagulation. In addition, long-term complica-
tions of dialysis, such as infection, fibrosis and cardiovascular events, are linked to the 
complement system. These results suggest that interventions targeting the complement 
system in dialysis could improve biocompatibility, dialysis efficacy, and long-term out-
come. Combined with the clinical availability to safely target complement in patients, 
the question is not if we should inhibit complement in dialysis, but when and how. The 
purpose of this review is to summarize previous findings and provide a comprehensive 
overview of the role of the complement system in both HD and PD.
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iNTRODUCTiON
An estimated 2.6 million people are treated for end-stage kidney disease (ESKD) worldwide (1). 
The majority of ESKD patients are dialysis-dependent. The choice between peritoneal dialysis (PD) 
and hemodialysis (HD) involves various determinants. Nonetheless, there is no major difference in 
Abbreviations: AP, alternative pathway; C1-INH, C1 esterase inhibitor; C3aR, C3a-receptor; C5aR, C5a-receptor; C5aRA, 
C5a-receptor antagonist; CARPA, complement activation-related pseudo allergy; MCP, membrane cofactor protein; CD55, 
decay accelerating factor; CD59, membrane attack complex-inhibitory protein; CP, classical pathway; CR1, complement 
receptor 1; CR3, complement receptor 3; CRP, C-reactive protein; CV-event, cardiovascular event; DAF, decay accelerating 
factor; ESKD, end-stage kidney disease; HD, hemodialysis; IgG, immunoglobulin G; IgM, immunoglobulin M; IL, interleukin; 
LDL, low-density lipoprotein; LP, lectin pathway; MAC, membrane attack complex; MBL, mannose-binding lectin; MCP-1, 
monocyte chemoattractant protein-1; PD, peritoneal dialysis; sC5b-9, soluble C5b-9; sCR1, soluble complement receptor 1; 
TGF-β, tumor growth factor beta; TNF-α, tumor necrosis factor alfa.
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mortality between HD and PD patients (2). Although consider-
able progress has been made in survival rates of dialysis patients, 
cardiovascular morbidity and mortality remain extremely high 
(3). Both traditional risk factors (such as hypertension, dys-
lipidemia, and diabetes), as well as non-traditional risk factors 
(such as oxidative stress, endothelial dysfunction and chronic 
inflammation), contribute to the high cardiovascular risk (4). In 
order to lower the high morbidity and mortality rates in dialysis 
patients, the chronic inflammation seen in these patients must 
be tackled. The systemic inflammation in dialysis patients can 
be attributed to the (remaining) uremia, the underlying renal 
disease, comorbidities, and dialysis-related factors (5). The latter 
represents an issue that has been present in dialysis throughout 
history, and still remains unresolved, namely bioincompatibility.
BiOCOMPATiBiLiTY
The term “biocompatible” refers to the “capacity of a material/
solutions to exist in contact with the human body without causing 
a (inappropriate) host response” (6). The biocompatibility of the 
materials used in dialysis remains an important clinical challenge. 
In HD, the membrane provokes an inflammatory response, as it is 
the site where blood has direct contact with a foreign surface (7). 
Additionally, PD fluids containing high glucose levels, hyperos-
molarity and acidic pH are considered biologically “unfriendly” 
and this lack of compatibility causes peritoneal membrane damage 
(8). Improving biocompatibility in HD and PD is a critical factor 
to ensure dialysis adequacy and enable long-term treatment (7–9). 
The challenge of biocompatibility is not confined to dialysis but 
equally important for other medical devices in contact with either 
tissue or blood (10). The incompatibility reaction is complex and 
poorly understood; however, platelets, leukocytes, the comple-
ment, and the coagulation system have been shown to be involved 
(11, 12). In general, incompatibility will lead to inflammation, 
thrombosis, and fibrosis (11–13). These events will negatively 
impact the clinical performance and lead to adverse events. The 
complement system is an important mediator of incompatibility 
because it can discriminate between self and non-self (14). In 
accordance, complement has been shown to be activated during 
cardiopulmonary bypass (15), low-density lipoprotein (LDL) 
apheresis (16), plasmapheresis (17), and immunoadsorption 
(18). Additionally, the complement system is also involved in 
biomaterial-induced complications of medical devices that are not 
in direct contact with the circulation, such as surgical meshes and 
prostheses (19, 20). Yet, it should be emphasized that the trigger 
by which complement is activated is different and depends on the 
properties of the biomaterial used (20). Proposed mechanisms of 
indirect complement activation include: (1) immunoglobulin G 
binding to the biomaterial initiating the classical pathway (CP); 
(2) lectin pathway (LP) activation by carbohydrate structures or 
acetylated compounds; or (3) activation of the alternative pathway 
(AP) by altered surfaces, e.g., plasma protein-coated biomaterials. 
In addition, complement initiators can also directly bind to the 
biomaterial, leading to complement activation (20). Irrespective 
of the pathway, complement activation always leads to the cleav-
age of C3, forming C3a and C3b (Figure 1). Increased levels of 
C3b result in the generation of the C5-convertase, cleaving C5 
in C5a, a powerful anaphylatoxin and chemoattractant, and C5b. 
Next, C5b binds to the surface and interacts with C6–C9, forming 
the membrane attack complex (MAC/C5b-9) (14).
HeMODiALYSiS
Hemodialysis is a general term including several techniques such 
as low or high-flux HD (diffusion-based dialysis) and online 
haemodiafiltration (combined convective and diffusive therapy). 
Overall, HD remains the most-used form of renal replacement in 
adult ESKD patients (1). The dialysis membrane can be divided 
into two main groups, cellulose-based and synthetic membranes 
(7, 21). In the past, HD membranes were based on cuprophane 
(a copper-substituted cellulose) because these were inexpensive 
and thin-walled. The disadvantage of cellulose-based membranes 
was the immunoreactivity due to the many free hydroxyl-groups. 
Subsequently, modified cellulosic membranes were developed to 
improve biocompatibility by replacing the free hydroxyl-groups 
with different substitutions (especially acetate). The following 
step was the development of “synthetic” membranes, such as 
polyacrylonitrile, acrylonitrile-sodium methallyl sulfonate, poly-
sulfone, polycarbonate, polyamide, and polymethylmethacrylate 
membranes. Nowadays, synthetic membranes are the most 
commonly used in clinical practice (21). The benefits of these 
membranes are the varying pore size and reduced immunoreac-
tivity. The complement system is critical in the bioincompatibility 
of extracorporeal circulation procedures, because complement is 
abundantly present in blood. Moreover, innate immune activa-
tion during HD is a neglected but potentially vital mechanism 
that contributes to the high morbidity and mortality in these 
patients (4).
Complement Activation in HD
In the 1970s, HD was already known to affect the complement 
system (22). Several studies have since then looked at comple-
ment activation during HD, the complement pathway responsible 
and additional mechanisms contributing to complement activa-
tion. In the past, an important adverse event in dialysis was the 
“first-use syndrome,” named after the fact that these reactions 
were most severe with new dialyzers. This incompatibility reac-
tion was the result of complement activation by the membrane 
and closely resembles the pseudo-anaphylactic clinical picture 
that is nowadays known as complement activation-related pseu-
doallergy (CARPA) (23, 24). Furthermore, these early studies 
provided important information on the kinetics of complement 
activation. During HD, C3 activation, resulting in the generation 
of C3a, peaks during the first 10–15 min, whereas terminal path-
way activation, resulting in C5a and C5b-9 formation occurs at a 
later stage of dialysis (25). Over the past decades, membranes have 
been developed with improved biocompatibility. Nonetheless, 
even with modern “biocompatible” HD membranes significant 
complement activation still occurs (23, 26, 27). During a single 
HD session soluble C5b-9 (sC5b-9) levels and C3d/C3-ratios in 
the plasma increase up to 70% (23, 26). Yet, this is most likely 
an underestimation of the amount of complement activation, 
since these values represent fluid phase activation. Complement 
activation takes place in the plasma (the fluid phase), but also on 
FigURe 1 | The complement system. A schematic view of activation of the complement system and its regulation. The classical pathway (CP) is initiated by C1q 
binding to immune complexes or other molecules (e.g., CRP), thereby activating C1r and C1s resulting in the cleavage of C2 and C4 thereby forming the 
C3-convertase (C4b2b). The lectin pathway (LP) is initiated by mannose-binding lectin (MBL), ficolins, or collectin-11 binding to carbohydrates or other molecules 
(e.g., IgA), thereby activating MASP-1 and MASP-2, forming the same C3-convertase as the CP. Subsequently, the C3-convertase cleavages C3 into C3a and C3b. 
Activation of the alternative pathway (AP) occurs via properdin binding to certain cell surfaces (e.g., LPS) or by spontaneous hydrolysis of C3 into C3(H2O). Next, 
binding of factor B creates the AP C3-convertase (C3bBb). Increased levels of C3b results in the formation of the C5-convertases, which cleaves C5 in C5a, a 
powerful anaphylatoxin, and C5b. Next, C5b binds to the surface and interactions with C6–C9, generating the membrane attack complexes (MAC/C5b-9). Several 
complement regulators (either soluble and membrane-bound) prevent or restrain complement activation. C1 esterase inhibitor (C1-INH) inhibits the activation of early 
pathway activation of all three pathways, while C4b-binding protein (C4BP) controls activation at the C4 level of the CP and LP. Factor I and factor H regulate the C3 
and C5-convertase. Furthermore, the membrane-bound inhibitors include complement receptor 1 (CR1), membrane cofactor protein (MCP) that acts as an 
co-factors for factor I and decay accelerating factor (DAF) which accelerates the decay of C3-convertases. The membrane-bound regulator Clusterin and CD59 
prevents the generation of the C5b-9.
3
Poppelaars et al. Complement Activation in PD and HD
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 71
surfaces (the solid phase) (14). Fittingly, in addition to fluid phase 
activation, complement depositions have also been shown on the 
surface of the HD membranes (28).
Different studies have tried to dissect the pathway responsi-
ble for complement activation in HD. Early evidence emerged 
from a study by Cheung et  al., demonstrating AP activation 
by cellulose membranes (29). Initially, the involvement of the 
CP or LP was excluded, since it was reported that plasma C4d 
concentrations remained unaffected during HD (30). However, 
others were able to show C4 activation by cellulose membranes 
(31, 32). The increase in C4d levels correlated with the rise in C3d 
levels, implying that the CP or LP is (at least partly) responsible 
for the complement activation seen in HD (32). More recently, a 
role for the LP was demonstrated in complement activation by 
polysulfone membranes (33, 34). An elegant study by Mares et al., 
using mass spectrometry, showed a 26-fold change in eluate-to-
plasma ratio for ficolin-2 (previously called L-ficolin), suggesting 
preferential adsorption by the membrane (33). A follow-up study 
using proteomics analysis of dialyzer eluates revealed that C3c, 
ficolin-2, mannose-binding lectin (MBL) and properdin were 
most enriched (28). In addition, plasma ficolin-2 levels decreased 
by 41% during one HD session, corresponding with the excessive 
adsorption to the membrane. The decrease in plasma ficolin-2 
levels was associated with C5a production and leukopenia during 
HD (28). The adsorption of properdin to the dialyzer, confirms 
earlier studies regarding AP activation by HD (28, 29). To sum-
marize, the principal mechanism of complement activation in 
HD is the binding of MBL and ficolin-2 to the membrane, result-
ing in LP activation; while, simultaneously, properdin and/or C3b 
bind to the membrane resulting in AP activation (Figure 2). The 
latter is supported by the evidence that in C4-deficient patients, 
systemic complement activation and C3b deposition on the HD 
membrane are reduced during dialysis but not abolished (31). 
These results show the importance of the LP, while demonstrating 
the crucial contribution of the AP.
A second mechanism that could modulate complement 
activation during HD is the loss of complement inhibitors via 
absorption to the membrane. In HD, polysulfone membranes 
FigURe 2 | Proposed model for complement activation in hemodialysis (HD). The principal mechanism leading to complement activation in HD is the binding of 
ficolin-2 to the membrane, resulting in lectin pathway activation. Simultaneously, properdin and/or C3b bind to the membrane resulting in alternative pathway 
activation. Complement activation will result in the formation of anaphylatoxins (C3a, C5a), opsonins (C3b, iC3b), and the membrane attack complex (C5b-9). First, 
complement activation leads to the upregulation of complement receptor 3 (CR3) allowing leukocytes to bind C3 fragments deposited on the membrane, leading to 
leukopenia. Second, CR3 on neutrophils is also important for the formation of platelet-neutrophil complexes, which contributes to thrombotic processes. 
Furthermore, C5a generation during HD leads to the expression of tissue factor and granulocyte colony-stimulating factor in neutrophils, shifting HD patients to a 
procoagulant state. Third, complement activation also promotes recruitment and activation of leukocytes resulting in the oxidative burst and the release of 
pro-inflammatory cytokines and chemokine’s. More specifically, the activation of neutrophils by C5a leads to the release of granule enzymes, e.g., myeloperoxidase 
(MPO).
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were shown to absorb factor H and clusterin (28, 33). Factor H 
is an important inhibitor of C3, while clusterin prevent terminal 
pathway activation thereby stopping the formation of C5a and 
C5b-9 (Figure 1) (14). The loss of these inhibitors would cause 
dysregulation of the AP, leading to further complement activation 
in the fluid phase (i.e., in the circulation) in HD patients.
effector Functions and Clinical 
implications of Complement Activation
Complement activation will lead to the generation of effector 
molecules, which can result in a variety of biological responses 
(14). In HD, the most important effector functions of complement 
activation are the induction of inflammation, promoting coagula-
tion and impaired host defense due to accelerated consumption 
of complement proteins (20, 35, 36).
The generation of C3a and C5a during HD promotes recruit-
ment and activation of leukocytes (37, 38). Leukocyte activation 
results in the oxidative burst and the release of pro-inflammatory 
cytokines and chemokine’s, such as interleukin (IL)-1β, IL-6, IL-8, 
tumor necrosis factor-α, monocyte chemoattractant protein-1, 
and interferon-γ. More specifically, the activation of PMNs by 
C5a leads to the release of granule enzymes such as myeloperoxi-
dase and elastase (39–41). Furthermore, complement activation 
in HD patients results in the upregulation of adhesion molecules 
on leukocytes, especially complement receptor 3 (CR3). The 
C5a-activated leukocytes will then bind C3 fragments (iC3b) 
deposited on the membrane via CR3, leading to leukopenia 
(20, 28, 39). Likewise, CR3 on PMNs is also important for the 
formation of platelet–PMN complexes, which can contribute to 
both inflammatory and thrombotic processes (42). The crosstalk 
between activation of the complement and coagulation system 
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has correspondingly been described in HD. It has been demon-
strated that C5a generation during HD leads to the expression of 
tissue factor and granulocyte colony-stimulating factor in PMNs, 
shifting HD patients to a procoagulative state (35). In conformity, 
plasma C3 levels have been shown to positively correlated with a 
denser clot structure in HD patients (43). On the other hand, the 
coagulation system has also been shown to impact complement 
activation (44).
Inflammation and coagulation are principally involved in the 
pathogenesis of cardiovascular disease. Accordingly, comple-
ment has been associated to the susceptibility to cardiovascular 
disease in HD patients (26, 27, 45–47). Plasma C3 levels, prior to 
a HD session, were found to be higher in patients who develop a 
cardiovascular event (CV-event) than HD patients who remained 
event-free. Moreover, an association was found between C3 levels 
and the development of CV-events (27). A similar trend of higher 
C3 levels in HD patients who develop a CV-event was seen in our 
study (26). A possible explanation would be that higher C3 levels 
prior to HD might reflect the potential for HD-evoked comple-
ment activation. Additionally, another association was found for 
baseline sC5b-9 levels with the occurrence of CV-events as well as 
mortality. This association was complex and showed an U-shaped 
relationship, indicating that both high and low sC5b-9 levels led 
to a higher risk, whereas HD patients with mid-range values were 
protected (27). Furthermore, a common factor H gene polymor-
phism was found to be an independent predictor of cardiovascu-
lar disease in HD patients (47). Homozygous HD patients for the 
Y402H polymorphism had an odds ratio of 7.28 for the develop-
ment of CV-events compared to controls. This polymorphism 
affects the binding sites for heparin and C-reactive protein (CRP) 
and it has, therefore, been hypothesized that the reduced binding 
of factor H to the patient’s endothelial cells would increase their 
risk of a CV-event. Alternatively, the link between the factor H 
polymorphism and the cardiovascular risk in HD patients could 
be mediated through CRP, since factor H binds CRP and thereby 
undermines its pro-inflammatory activity (48, 49). The Y402H 
polymorphism of factor H results in inadequate binding to CRP 
and thus leaves the pro-inflammatory activity of CRP unchecked. 
Furthermore, several studies have demonstrated that CRP levels 
in HD patients are associated to cardiovascular mortality (50–52). 
Buraczynska et al. revealed that in HD patients the complement 
receptor 1 (CR1) gene polymorphism C5507G is independently 
associated with the susceptibility for cardiovascular disease (46). 
Whether this effect is mediated via the complement inhibitory 
capacity of CR1 or via the recently discovered function of CR1 in 
the binding and clearance of native LDL remains to be elucidated 
(53). Another study showed that low serum C1q-adiponectin/
C1q ratios were linked to cardiovascular disease in HD patients 
(45). The mechanism behind this connection is not understood 
but it has been demonstrated that adiponectin protects against 
activation of C1q-induced inflammation (54). Thus, in HD 
patients increased complement activation, as well as increased 
complement activity and the loss of complement inhibitors have 
all been linked to a higher risk of cardiovascular disease (Table 1). 
Recently, our group showed that low MBL levels are also associ-
ated with the occurrence of cardiovascular disease in HD patients 
(26). The higher risk in these patients was attributed to CV-events 
linked to atherosclerosis. In support of this, low MBL levels have 
been linked to enhanced arterial stiffness in HD patients (55). 
Accordingly, Satomura et al. demonstrated that low MBL levels 
were an independent predictor of all-cause mortality in HD 
patients (56). We, therefore, postulate that in HD patients, low 
MBL levels promote cardiovascular disease by enhancing athero-
sclerosis due to the inadequate removal of atherogenic particles.
In HD patients, little is known about the changes in comple-
ment components overtime. The plasma levels of C3 have been 
shown to decrease after 12 months compared to baseline (27). In 
this study, the C3 levels also negatively correlated with the dialysis 
vintage. In addition, the ability to activate complement has also 
been shown to be decreased in HD patients compared to healthy 
controls (23). In theory, these acquired deficiencies of comple-
ment proteins could explain the higher infection and sepsis 
risk seen in HD patients. Conversely, there was no association 
between low MBL levels and the risk of infection in HD patients 
(57). However, the authors concluded that this might be due to 
a compensation mechanism of higher ficolin-2 and MASP-2 
levels in MBL-deficient individuals. Furthermore, another 
study found that long-term HD patients have decreased levels 
of clusterin, factor B and factor H compared to short-term HD 
patients (58). Thus far, no study has analyzed the link between 
HD-acquired complement deficiencies and infection risk. The 
clinical consequences of the HD-induced ficolin-2 reduction 
would be the most interesting to examine (28, 33). It is highly 
likely that this reduction would have a tremendous impact on HD 
patients’ health and outcome. A genetic deficiency in ficolin-2 
has not been reported to date, highlighting the essential function 
of this component within host defense. In conformity, ficolin-2 
has been shown to be involved in the elimination of numerous 
pathogens (59).
Therapeutic Options
Several types of interventions have been proposed or tested in 
HD patients to decrease inflammation or target cardiovascular 
risk factors with mixed success. Hence, the clinical need for bet-
ter therapeutic options that limit the inflammation and decrease 
cardiovascular risk in HD patients is on-going. The complement 
system is considered to be a promising target during HD to 
limit the inflammation and decrease cardiovascular risk (60). 
Therapies modulating HD-induced complement activation have 
focused on three treatment strategies: (1) reduction in the com-
plement activating-capacity of the HD membrane; (2) the use of 
non-specific complement inhibitors (e.g., anticoagulants with a 
complement inhibitory property); and (3) specific complement-
directed therapies.
Prevention is better than cure; therefore, creating a truly 
biocompatible membrane would, therefore, be ideal to prevent 
complement activation during HD. Much progress has been 
made with the development of more biologically compatible 
membranes by surface modifications and reducing protein reten-
tion. Today, the most common HD membranes contain sulfonyl-
groups (7). To further improve biocompatibility, it is vital to 
understand the structures that initiate complement activation as 
it has the potential to develop HD membranes with enhanced 
biocompatibility. In modern HD membranes, ficolin-2 seems to 
TABLe 1 | The association between complement proteins and morbidity and mortality in HD patients.
Study Complement 
protein
Outcome Associationa Possible mechanism
Poppelaars et al. 
(26, 67)
MBL levels CV-events Low MBL levels OR = 3.98 
(1.88–8.24)
Low MBL levels promote atherosclerosis due to the inadequate removal 
of atherogenic particles
Satomura et al. (56) MBL levels All-cause 
mortality
Low MBL levels OR = 7.63 
(2.24–25.96)
Low MBL levels promote atherosclerosis due to the inadequate removal 
of atherogenic particles
Kishida et al. (45) C1q-adiponectin 
levels
CV-events Low C1q-adiponectin levels Adiponectin protects against activation of C1q-induced inflammation
Lines et al. (27) C3 levels CV-events Higher C3 levels (per 0.1 mg/ml) 
HR = 1.20 (1.01–1.42)
Increased complement activity
Lines et al. (27) sC5b-9 levels CV-events Low and high sC5b-9 levels (1) Increased complement activation.









Factor H gene 
polymorphism 
(Y402H)
CV-events The CC genotype OR = 7.28 
(5.32–9.95)
(1) The loss of complement inhibition, leading to complement 
activation.






CV-events The GG genotype OR = 3.44 
(2.23–5.3)
(1) The loss of complement inhibition, leading to complement 
activation.
(2) Reduced binding and clearance of native low-density lipoprotein by 
CR1.
aData are presented as hazard or OR plus 95% confidence interval.
OR, odds ratio; HR, hazard ratio; HD, hemodialysis; MBL, mannose-binding lectin; CR1, complement receptor 1; CV-event, cardiovascular event; sC5b-9, soluble C5b-9.
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be an important mediator in HD-induced complement activa-
tion (28, 33). Ficolin-2 is unfortunately a highly promiscuous 
molecule with numerous binding partners, several of which are 
acetylated compounds (59).
Anticoagulants have been used extensively to render biomate-
rial-blood incompatibility, through inhibition of the coagulation, 
contact and complement system. The effect of citrate anticoagula-
tion on complement activation has widely been studied in HD. 
Citrate has calcium-chelating properties and thereby reduces 
complement activation (61, 62). During the initial phase of HD 
with cellulose membranes, citrate anticoagulation reduced C3a 
levels by almost 50% compared to heparin (63). However, no com-
plement inhibition was seen by citrate anticoagulation during HD 
in other studies with cellulose or synthetic membranes (64–66). 
Heparinoids are also known to prevent complement activation, 
although this inhibition is strictly concentration dependent (67). 
Although heparin has been tested extensively in HD, sadly none 
of these studies determined the effect on complement activation.
In the past decade, numerous complement inhibitors have 
been developed; two are currently used in the clinics and others 
are now undergoing clinical trials. Purified C1 esterase inhibitor 
(C1-INH) is a protease that is clinically used to treat hereditary 
angioedema. Eculizumab, a C5 antibody is used for the treatment 
of paroxysmal nocturnal hemoglobinuria and atypical hemolytic 
uremic syndrome (14, 68). In HD, specific complement-directed 
therapies have predominantly been evaluated in experimental 
settings, still valuable information has been uncovered and shown 
that the use of complement inhibitors are a promising tool to 
reduce the inflammatory response and subsequent consequences 
in these patients (60). The potential of complement inhibition in 
HD is further underlined by the successful use of complement 
inhibitors for biomaterial-induced complement activation in 
cardiopulmonary bypass systems (19). In patients undergoing 
cardiopulmonary bypass surgery, treatment with soluble CR1 
(sCR1/TP30), an inhibitor of C3, lead to a decrease in mortality 
and morbidity as well as a reduced need for intra-aortic balloon 
pump support (69). Consequently, soluble complement inhibi-
tors may be equally effective in HD, since there is the recurrent 
need of complement inhibition for short periods. Specifically, the 
short half-life of sCR1 matches the need for restricted comple-
ment inhibition in HD, which is only needed during dialysis, 
after which complement activity should be reestablished between 
sessions. This approach would also prevent complications of 
long-term immunosuppression. In a pre-clinical monkey model 
of HD, another C3-inhibitor (compstatin) was used to attenu-
ate HD-induced complement activation (70). Despite the use 
of HD membranes with high biocompatibility and standard 
heparin treatment in their study, severe complement activation 
still occurred in monkeys. In this study, animals received a bolus 
injection prior to the HD and a continuous infusion of compsta-
tin during the 4 h HD procedure. Treatment completely blocked 
complement activation and C3 activation products stayed at basal 
levels throughout the HD session. Strikingly, a second treat-
ment regimen with only a bolus injection of compstatin at the 
start of the session was also sufficient to abolished complement 
activation throughout the procedure. Furthermore, complement 
inhibition lead to the increase of IL-10, an anti-inflammatory 
cytokine. Unfortunately, the effect of complement inhibition on 
other inflammatory markers could not be assessed, since one HD 
session was insufficient to induce substantial levels of pro-inflam-
matory cytokines. Next to inhibition of the central component 
C3, blockage of early complement components may be equally 
successful. C1-INH forms a therapeutic option, since HD leads to 
LP activation and C1-INH could attenuate this (67). Additionally, 
C1-INH also affects the coagulation and contact system, which 
could add to the success of this therapeutic approach. Given the 
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strong involvement of complement activation effector molecules 
in HD, more specifically C5a, another attractive option would be 
the inhibition of C5 or C5a-receptor antagonists (C5aRA) (35). 
This could be either done by the anti-C5 antibody or by C5aRA. 
Eculizmab blocks the generation of C5a and C5b-9 and could 
thus be more effective than C5aRA. However, the long half-life 
and the high costs form important disadvantages. In contrast, 
C5aRA tends to be more cost-effective (71). These drugs could 
significantly reduce activation of leukocytes and thereby inflam-
mation in HD. Currently, the most likely candidate to be used in 
HD is PMX-53, a C5aRA, since this compound is currently tested 
in different clinical trials (72). Another promising approach is 
coating biomaterials with complement inhibitors (20). One of 
these molecules, the 5C6 peptide is a molecule that has strong 
binding affinity toward factor H without modifying its inhibitory 
activity. More importantly, polystyrene surfaces coated with 5C6 
were shown to bind factor H and thereby prevent complement 
activation when exposed to human plasma, thus enhancing 
biocompatibility (73). However, it is unknown whether the 
reduction of systemic factor H levels by 5C6 during HD could 
have undesirable consequences, such as seen in factor H-deficient 
individuals. Finally, the cost of the different complement inhibi-
tors should be taken into account, considering the high frequency 
of treatments required in HD patients.
PeRiTONeAL DiALYSiS
Peritoneal dialysis is the most common used dialysis technique 
at home and is equally effective as HD for the treatment of CKD 
(74). Nevertheless, the advantages of PD include; better preserva-
tion of residual renal function, lower infectious risk and higher 
satisfaction rates. Despite the good results seen with PD, this 
dialysis technique remains underused (1). In PD, unlike in HD, 
no synthetic membrane is used. In contrast, the peritoneum in 
the abdominal cavity of the patients acts as a semi-permeable 
membrane allowing diffusion between the dialysis fluid and 
the circulation. The osmotic gradient during PD is based on 
high glucose levels in the dialysate. However, glucose acts as a 
double edge sword, since it serves as an osmotic agent but it is 
also responsible for the incompatibility reaction. The peritoneal 
membrane is made up of an inner mesothelial layer and these 
cells are, therefore, directly in contact with the dialysis fluid. 
Long-term exposure to dialysate leads to tissue remodeling of this 
layer resulting in peritoneal fibrosis (75). This progressive fibrosis 
forms a major limitation for chronic PD treatment. Another 
common complication in PD is peritonitis (76). Patients who 
develop peritonitis can have irreversible peritoneum damage, 
PD failure and significant morbidity or even mortality. For this 
reason, avoiding PD failure due to peritonitis or fibrosis remains 
a challenge for nephrologists (77).
Complement Activation in PD
The link between the complement system and PD seems less 
obvious, because there is no direct contact with blood. However, 
mesothelial cells produce and secrete different complement fac-
tors, including C4, C3, and C5 till C9 (78, 79). In accordance, 
different studies have found the presence of complement in the 
peritoneal dialysate. Additionally, the amount of C3 in the PD 
fluid does not depend on the serum concentration, suggesting 
that the C3 originates from local production (80). The study by 
Oliveira et  al. found strong protein abundance of Factor D in 
six adult PD patients (81), whereas a similar approach in 76 PD 
patients by Wen et al. found significant protein expression of C4 
and C3 only (82). Altogether, proteomic analyses of the dialysate 
of healthy PD patients has revealed the presence of C4, C3, Factor 
B, Factor D, Factor H, Factor I, and C9 (81–85). Proteomic profil-
ing in the peritoneal fluid of children identified a total number 
of 189 proteins, of which 18 complement components (84). The 
discrepancies between the various proteomic studies could be 
explained by differences in the underlying cause of renal failure, 
since diabetic patients on PD have been shown to have lower 
levels of C4 in the dialysate compared to controls (83). Obviously, 
other patient’s characteristics such as ethnicity and differences in 
the accuracy and sensitive of the analysis have to be taken into 
account as well. Complement production by mesothelial cells 
has been shown to be increased in uremic patients and it can 
be further stimulated upon exposure to PD solutions containing 
glucose (78, 79). Next to complement production; mesothelial 
cells also express important complement regulators; e.g., MCP, 
DAF, and CD59 (79, 80).
Systemically, PD patients have lower MBL levels compared 
to HD patients and healthy controls, even after adjusting for the 
effect of mutations (86). This could indicate loss of systemic MBL 
via the peritoneal route, independent of the reduced renal func-
tion. However, MBL has so far not been assessed in peritoneal 
dialysates. Furthermore, serum levels of C1q, C4, C3d, factor D, 
and properdin were shown to be higher in pediatric PD patients 
compared to healthy controls, however, not in comparison to 
patients with ESKD (87). Overall, the higher plasma levels of the 
complement components are likely caused by increased synthesis 
by the liver due to the pro-inflammatory state in ESKD patients. 
Moreover, the increased levels of C3d in PD patients are believed 
to be the consequence of reduced elimination of factor D by the 
kidney, creating enhanced AP activation. However, while sys-
temic complement activation (the fluid phase) is similar between 
PD patients and patients with ESKD, higher intravascular com-
plement depositions (solid phase) have been shown in children 
with PD compared to non-PD children with ESKD. Omental and 
parietal arterioles from PD patients demonstrated a higher pres-
ence of C1q, C3d, and C5b-9 (88).
Evidence has also been provided for complement activation 
in the peritoneal cavity in PD patients (80, 89). Previously, it was 
demonstrated that the dialysate/serum ratios of factor D and C3d 
were elevated in PD, whereas the dialysate/serum ratios of C3, 
C4, and properdin were decreased (89). The high dialysate levels 
of C3d demonstrate local complement activation, while the com-
paratively low dialysate/serum ratios of complement components 
are likely caused by intraperitoneal complement consumption. In 
accordance, the presence of sC5b-9 in the peritoneal dialysate has 
also been shown. In the dialysate of PD patients, sC5b-9 levels 
up to 200 pg/µg of total protein level have been reported (80). 
Considering the high molecular weight of sC5b-9 (>1,000 kDa), 
it is very likely that the sC5b-9 in the dialysate is produced in 
the peritoneal cavity and does not originate from the circulation.
FigURe 3 | Proposed model for complement activation in peritoneal dialysis (PD). In PD patients, mesothelial cells produce and secrete different complement 
factors. One of the proposed mechanisms of complement activation in PD patients is that PD therapy decreases the expression of complement regulators such as 
CD55 and CD59 on the peritoneal mesothelium, leading to local complement activation. In addition, cellular debris as a result of direct peritoneal damage by 
bioincompatible PD fluids as well as antibodies against microorganisms could contribute to local complement activation during PD. Complement activation will result 
in the formation of anaphylatoxins (C3a, C5a), opsonins (C3b, iC3b), and the membrane attack complex (C5b-9). First, complement activation leads to the influx of 
leukocytes, predominantly neutrophils. Second, complement activation increased the production of thrombin anti-thrombin complexes and fibrin exudation on the 
surface of the injured peritoneum. Altogether, these events indicate the activation of the coagulation system. Third, complement activation during PD leads to direct 
damage of the peritoneum. Moreover, recent evidence suggests that complement activation promotes the progression to fibrosis after tissue injury. In PD, 
complement activation could stimulate mesothelial cells to undergo epithelial-to-mesenchymal transition, resulting in the accumulation of myofibroblasts and 
consequently peritoneal fibrosis.
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One of the proposed mechanisms of complement activation 
in PD patients is that PD therapy modifies the expression of 
complement regulators on the peritoneal mesothelium, lead-
ing to local complement activation (Figure  3). In accordance, 
CD55 expression is lower on mesothelial cells from PD patients 
than non-CKD patients and the reduced expression of CD55 is 
accompanied by higher peritoneal levels of sC5b-9 (80). Likewise, 
complement regulators were also shown to be downregulated in 
arterioles of PD patients. Furthermore, the C5b-9 deposition 
seen in the arterioles of PD patients correlated with the level of 
dialytic glucose exposure (88). However, this is probably not the 
only mechanism responsible for complement activation in PD 
patients. Hypothetically, cellular debris as a result of direct peri-
toneal damage by bioincompatible PD fluids as well as antibodies 
against microorganisms could contribute to local complement 
activation during PD. Unfortunately, most of the reviewed studies 
are relatively old and there is, therefore, a need for novel studies 
to assess the effect of newer PD solutions on complement produc-
tion and activation.
effector Functions and Clinical 
implications of Complement Activation
During PD, complement activation occurs locally within the 
peritoneal cavity and leads to the generation of opsonins, ana-
phylatoxins, and the MAC. The effects of complement activation 
during PD include the induction of tissue injury, inflammation, 
coagulation, and fibrosis. However, complement activation in PD 
patients has also been linked to long-term effects such as cardio-
vascular risk (88). In different experimental models, complement 
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activation during PD leads to direct damage of the peritoneum. 
The complement-induced peritoneal damage seems to be medi-
ated via activation of the terminal pathway, specifically C5a and 
C5b-9 (90–92). Additionally, complement activation leads to 
inflammation. In a rat model of peritoneal fluid infusion, the 
numbers of neutrophils increased significantly overtime, and this 
process was largely dependent on C5 activation. In conformity, 
intraperitoneal injections with C3a and C5a in mice lead to the 
influx of leukocytes, predominantly neutrophils (93). The effect 
of C5a is mediated via C5aR1, while the effect of C3a is presum-
ably mediated via the C3a-receptor. The crosstalk between activa-
tion of the complement and coagulation system has also been 
described in PD. Thrombin anti-thrombin complexes increased 
significantly in experimental models of PD and this process was 
partly dependent on C5 activation (92). Mizuno et al. showed that 
intraperitoneal complement activation leads to fibrin exudation 
on the surface of the injured peritoneum (94). Altogether these 
findings indicate that activation of the coagulation system by the 
PD therapy is at least (partly) complement dependent. The fibrin 
exudate can also be a sign of PD-associated fibrosis.
The link between fibrosis and complement is relatively new; 
nevertheless, recent evidence suggests that complement activa-
tion promotes the progression to fibrosis after tissue injury (95). 
In PD, high peritoneal transport is associated with progression of 
peritoneal fibrosis (96). Proteomics analysis of PD fluid showed 
enhanced expression of C3 in patients with high transporter 
status, while expression of C4 is lower in low transporters (82, 
97). Furthermore, in PD mesothelial cells undergo epithelial-
to-mesenchymal transition, resulting in the accumulation of 
myofibroblasts and consequently peritoneal fibrosis (98). In 
other disease models, complement has been shown to induce 
epithelial-to-mesenchymal transition (99). This effect is medi-
ated via the C5aR1, since in rodent models of infection–induced 
peritoneal fibrosis C5aR1−/− mice were protected against fibrosis 
(100). The C5aR1 is also involved in the production of profibrotic 
and inflammatory mediators by peritoneal leukocytes (100). In 
addition, Bartosova et al. reported that in the peritoneal arterioles 
of PD patient’s, high abundance of complement deposition was 
found to correlate with TGF-b signaling (88). More specifically, 
C1q and C5b-9 deposition were associated with an increased 
phosphorylation of SMAD2/3, and enhanced vasculopathy. 
Interestingly, the TGF-b–SMAD pathway has also been recently 
linked to cardiovascular disease (101). Encapsulating peritoneal 
sclerosis is another long-term complication of PD, which is the 
result of abnormal thickening and fibrosis of the peritoneum, 
leading to a fibrous cocoon thereby encapsulating the intestines 
causing obstruction (102). The exact cause of this rare complica-
tion is unknown, but it is linked to the bioincompatibility of the 
glucose-based PD solutions (103). The bioincompatibility of these 
solutions presumably promotes the expression TGF-b, thereby 
stimulating the transition of mesothelial cells to myofibroblasts. 
Recently, a prospective proteomics study identified complement 
components as a possible biomarker of encapsulating peritoneal 
sclerosis (85). Factors B and factor I were elevated in the PD fluid 
of patients up to 5 years prior to developing encapsulating perito-
neal sclerosis. In patients with stable membrane function, factor 
I was present in the PD fluid in lower amounts and decreased 
overtime, while factor B was barely detectable in the PD fluid of 
controls. However, whether the elevated levels of these comple-
ment factors are merely an acute phase response or involved in 
the pathogenesis remains to be investigated. Yet, based on the 
current literature, complement activation is likely to play a role 
in the mechanisms of peritoneal fibrosis. Nevertheless, additional 
studies are needed to further elucidate the specific role of the 
complement system in this process.
Peritonitis is another common complication with significant 
morbidity and mortality. Complement has been proposed to be 
involved in the risk of PD patients for peritonitis. First, a variation 
in the FCN2 gene was shown to be more prevalent in PD patients 
with a history of peritonitis (104). In addition, local activation 
will lead to a further decline of already low levels of complement 
components in PD fluid and may thereby additionally impair 
host defense. Complement activation products have also been 
suggested as a biomarker during peritonitis. Mizuno et al. showed 
that C4, C3, and sC5b-9 levels in the peritoneal fluid are signifi-
cantly higher in PD patients with poor prognosis after peritonitis 
(105). Complement markers in peritoneal fluid have, therefore, 
the potential to serve as a biomarker for the prediction of the 
prognosis of PD-related peritonitis. Finally, the risk of peritonitis 
could form a major Achilles heel for complement inhibition in PD.
Therapeutic Options
Treatment aimed at attenuating or blocking complement activa-
tion in PD has mostly focused on the terminal pathway. The 
advantage of this approach is the elimination effector functions 
of C5a and/or C5b-9, while proximal complement functions stay 
intact. In vitro, inhibition of the C5aR1 on peritoneal leukocytes, 
isolated from PD fluid, reduced bacteria-induced profibrotic 
(TGF-β) and inflammatory (IL-6 and IL-8) mediator produc-
tion (100). In addition, the systemic administration of a C5aR1 
antagonist in a rat model of PD prevented influx of inflammatory 
cells and reduced tissue damage of the peritoneal cavity (91). 
Furthermore, blockage of C5 in PD improved ultrafiltration 
and additionally reduced activation of the blood clotting system 
(92). Other studies have confirmed these results; showing that 
C5 blockade significantly increased the ultrafiltration volume via 
reduced peritoneal glucose transport, most likely by preventing 
C5a-induced vasodilatation (106). In contrast, C3 inhibition 
through complement depletion by cobra venom factor, also led 
to diminished chemoattractant release, neutrophil recruitment 
and enhanced ultrafiltration (106). Anticoagulants have also 
been tested for the treatment of the inflammatory reaction to PD 
fluids (106, 107). The addition of low-molecular-weight heparin 
to the PD fluid not only prevented thrombin formation but also 
inhibited the complement activation, neutrophil recruitment, 
and improved ultrafiltration (107). In brief, results about comple-
ment inhibition in PD look promising, but many hurdles remain 
to be solved.
CONCLUSiON
In conclusion, biocompatibility remains an important clinical 
challenge within dialysis. Due to bioincompatibility, comple-
ment is systemically activated during HD, while PD leads to local 
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complement activation. Moreover, important effector functions 
of complement activation include promoting inflammation and 
coagulation. In addition, long-term complications of dialysis, 
such as infection, fibrosis, and cardiovascular events, are linked 
to the complement system. These results indicate the possibility 
for complement interventions in dialysis to improve biocompat-
ibility, dialysis efficacy, and long-term outcome.
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